Hydroxychloroquine in nephrology: current status and future directions

[1]  Xiaoyuan Ning,et al.  Treatment with rituximab and hydroxychloroquine in a patient with membranous nephropathy and diabetic nephropathy: A case report , 2023, Diabetic Nephropathy.

[2]  Waleed Ahmed El-Shahaby,et al.  Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial , 2023, European Journal of Pediatrics.

[3]  G. Remuzzi,et al.  Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. , 2022, Kidney international.

[4]  T. Nishino,et al.  Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling , 2022, Clinical and Experimental Nephrology.

[5]  Hyon K. Choi,et al.  Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares. , 2022, JAMA.

[6]  C. Ponticelli,et al.  Autophagy in lupus nephritis: A delicate balance between regulation and disease. , 2022, Autoimmunity reviews.

[7]  Sachin Agarwal,et al.  Hydroxychloroquine Reduces Proteinuria in Indian Patients With IgA Nephropathy , 2022, Kidney international reports.

[8]  I. Bruce,et al.  Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort , 2021, Annals of the Rheumatic Diseases.

[9]  Ming-hui Zhao,et al.  Effects of hydroxychloroquine on proteinuria in membranous nephropathy , 2021, Journal of Nephrology.

[10]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[11]  Zen Margherita,et al.  Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. , 2021, Rheumatology.

[12]  Qiquan Sun,et al.  Hydroxychloroquine Inhibits Macrophage Activation and Attenuates Renal Fibrosis After Ischemia-Reperfusion Injury , 2021, Frontiers in Immunology.

[13]  T. Mochizuki,et al.  Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease , 2021, Kidney medicine.

[14]  F. Ciccia,et al.  Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study , 2021, Lupus.

[15]  Sudhir V. Shah,et al.  Management of Cardiovascular Disease in Kidney Disease Study: Rationale and Design , 2021, American Journal of Nephrology.

[16]  M. Marmor,et al.  American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity , 2021, Arthritis & rheumatology.

[17]  Omar F. AbouEzzeddine,et al.  Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes , 2021, Frontiers in Neurology.

[18]  I. Matsumoto,et al.  QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine , 2021, Modern rheumatology.

[19]  M. Konig,et al.  Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus , 2021, Arthritis & rheumatology.

[20]  Gene Kim,et al.  Chloroquine- and Hydroxychloroquine–Induced Cardiomyopathy: A Case Report and Brief Literature Review , 2020, American journal of clinical pathology.

[21]  F. Guengerich,et al.  Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. , 2020, Current drug metabolism.

[22]  Hong Zhang,et al.  Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study , 2020, BMC Nephrology.

[23]  A. Pareek,et al.  Hydroxychloroquine and QT prolongation: reassuring data in approved indications , 2020, Rheumatology advances in practice.

[24]  B. Bart,et al.  Effects of hydroxychloroquine treatment on QT interval , 2020, Heart Rhythm.

[25]  Jing-Yang Huang,et al.  Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus , 2020, Annals of the Rheumatic Diseases.

[26]  M. Becker,et al.  QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review , 2020, Heart Rhythm.

[27]  Joshua D. Brown,et al.  Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine , 2020, Research in Social and Administrative Pharmacy.

[28]  E. Frangou,et al.  2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[29]  L. Magder,et al.  Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy , 2020, Arthritis & rheumatology.

[30]  Hsin-Hua Chen,et al.  Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study , 2020, BMC Infectious Diseases.

[31]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.

[32]  Christie M. Bartels,et al.  Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta‐Analysis , 2020, Arthritis care & research.

[33]  B. Yoo,et al.  Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine , 2019, Lupus.

[34]  Hong Zhang,et al.  Autophagy in Immune-Related Renal Disease , 2019, Journal of immunology research.

[35]  Hong Zhang,et al.  Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study , 2019, BMC Nephrology.

[36]  D. Wojdyla,et al.  Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort , 2019, Lupus.

[37]  Hong Zhang,et al.  Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  Y. Cho,et al.  Factors associated with aggravation of tubulointerstitial damage on repeat biopsies in lupus nephritis patients with treatment failure. , 2019, Clinical and experimental rheumatology.

[39]  Ø. Molberg,et al.  Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort , 2019, Lupus.

[40]  H. Cha,et al.  Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia , 2019, Lupus.

[41]  J. An,et al.  Inhibition of Cyclic GMP‐AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1‐Deficient Mice , 2018, Arthritis & rheumatology.

[42]  Xingdong Zhou,et al.  Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion , 2018, Autophagy.

[43]  A. Lotery,et al.  The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary , 2018, Eye.

[44]  F. Roubille,et al.  Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature , 2018, Drug Safety.

[45]  C. Mok,et al.  Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort , 2018, Lupus.

[46]  Hong Zhang,et al.  Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy , 2018, American Journal of Nephrology.

[47]  Bin Wang,et al.  Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation , 2018, Cell Death & Disease.

[48]  C. Sergi,et al.  Chloroquine‐induced cardiomyopathy: a reversible cause of heart failure , 2018, ESC heart failure.

[49]  J. Andreu,et al.  Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. , 2017, Seminars in arthritis and rheumatism.

[50]  Xuemei Li,et al.  Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy , 2017, International Urology and Nephrology.

[51]  K. Lackner,et al.  Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase , 2016, Annals of the rheumatic diseases.

[52]  P. Ravani,et al.  Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. , 2016, Journal of autoimmunity.

[53]  L. Herrinton,et al.  Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials , 2016, The Journal of Rheumatology.

[54]  R. Correa-Rotter,et al.  Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population , 2016, Clinical Rheumatology.

[55]  D. D’cruz,et al.  AB0531 The Role of Hydroxychloroquine in ANCA Positive and Negative Vasculitis , 2016 .

[56]  Wei Tang,et al.  Toll-like receptors: potential targets for lupus treatment , 2015, Acta Pharmacologica Sinica.

[57]  H. Law,et al.  The Role of Autophagy in Lupus Nephritis , 2015, International journal of molecular sciences.

[58]  Oleg K. Karaduta,et al.  Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease , 2015, PloS one.

[59]  K. Rainsford,et al.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases , 2015, Inflammopharmacology.

[60]  V. Shah,et al.  Hydroxychloroquine retinopathy: A review of imaging , 2015, Indian journal of ophthalmology.

[61]  W. Winkelmayer,et al.  Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis , 2015, Arthritis & rheumatology.

[62]  S. A. Abdel Galil,et al.  Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report , 2015, Lupus.

[63]  M. Dall'era,et al.  Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome , 2015, Lupus Science & Medicine.

[64]  J. An,et al.  Cutting Edge: Antimalarial Drugs Inhibit IFN-β Production through Blockade of Cyclic GMP-AMP Synthase–DNA Interaction , 2015, The Journal of Immunology.

[65]  M. Marmor,et al.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. , 2014, JAMA ophthalmology.

[66]  Y. Molad,et al.  Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study , 2014, Clinical Rheumatology.

[67]  S. Galdino,et al.  Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients , 2013, Clinics.

[68]  I. Okpechi,et al.  Outcome of patients with membranous lupus nephritis in Cape Town South Africa. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[69]  Jonathan Barratt,et al.  An update on the pathogenesis and treatment of IgA nephropathy. , 2012, Kidney international.

[70]  Z-H Zheng,et al.  Predictors of survival in Chinese patients with lupus nephritis , 2012, Lupus.

[71]  J. Reveille,et al.  Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort , 2012, Lupus.

[72]  D. Yap,et al.  Dyslipidaemia in patients with lupus nephritis , 2011, Nephrology.

[73]  Umberto D'Alessandro,et al.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria , 2011, Malaria Journal.

[74]  U. Švajger,et al.  Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines , 2011, The Journal of Immunology.

[75]  G. Alarcón,et al.  Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. , 2010, Arthritis and rheumatism.

[76]  J. Narbutt,et al.  Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus , 2010, Lupus.

[77]  J. Reveille,et al.  Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. , 2009, Arthritis and rheumatism.

[78]  H. Anders,et al.  Lupus nephritis , 2009, Nature Reviews Disease Primers.

[79]  Pojen P. Chen,et al.  Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. , 2008, Blood.

[80]  M. Ramos-Casals,et al.  Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival , 2008, Lupus.

[81]  S. Kalia,et al.  New concepts in antimalarial use and mode of action in dermatology , 2007, Dermatologic therapy.

[82]  B. Amichai,et al.  Cutaneous hyperpigmentation during therapy with hydroxychloroquine. , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[83]  J. Reveille,et al.  Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) , 2007, Annals of the rheumatic diseases.

[84]  J. Piette,et al.  Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus , 2007, Annals of the rheumatic diseases.

[85]  G. Ruiz-Irastorza,et al.  Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus , 2006, Lupus.

[86]  L. Magder,et al.  Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis , 2006, Lupus.

[87]  C. Cho,et al.  Hydroxychloroquine potentiates Fas‐mediated apoptosis of rheumatoid synoviocytes , 2006, Clinical and experimental immunology.

[88]  D. Jue,et al.  Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes , 2006 .

[89]  I. Rosner,et al.  The Reduction of Serum B‐Lymphocyte Activating Factor levels following Quinacrine Add‐On Therapy in Systemic Lupus Erythematosus , 2006, Scandinavian journal of immunology.

[90]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. , 2005, Arthritis and rheumatism.

[91]  J. Reveille,et al.  What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading? , 2004, Autoimmunity reviews.

[92]  A. Terman,et al.  Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[93]  E. Tsakonas,et al.  A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus , 1998 .

[94]  B. Adams-Huet,et al.  Hydroxychloroquine Effects on Lipoprotein Profiles (the HELP trial): A Double‐Blind, Randomized, Placebo‐Controlled, Pilot Study In Patients With Systemic Lupus Erythematosus , 1997, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[95]  D. Furst.  Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases , 1996, Lupus.

[96]  K. Greer,et al.  CUTANEOUS HYPERPIGMENTATION CAUSED BY SYSTEMIC DRUGS , 1992, International journal of dermatology.

[97]  R. Day,et al.  Bioavailability of hydroxychloroquine tablets in healthy volunteers. , 1989, British journal of clinical pharmacology.

[98]  G. E. Gresham,et al.  The efficacy of antimalarials in systemic lupus erythematosus. , 1988, The Journal of rheumatology.

[99]  R. Luqmani,et al.  Hydroxychloroquine retinopathy , 2017, Eye.